Less Ads, More Data, More Tools Register for FREE

Pin to quick picksZotefoams Regulatory News (ZTF)

Share Price Information for Zotefoams (ZTF)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 510.00
Bid: 510.00
Ask: 520.00
Change: -10.00 (-1.92%)
Spread: 10.00 (1.961%)
Open: 526.00
High: 526.00
Low: 510.00
Prev. Close: 520.00
ZTF Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Trading Update and Chair Succession

24 May 2023 07:00

RNS Number : 4142A
Zotefoams PLC
24 May 2023
 

Zotefoams plc

("Zotefoams" or "Group")

 

Trading Update and Chair Succession

 

24 May 2023 - Zotefoams, a world leader in cellular materials technology, today provides a trading update for the four months ended 30 April 2023, ahead of its Annual General Meeting to be held today at 10am at 675 Mitcham Road, Croydon, CR9 3AL.

At this meeting Steve Good, Chair of Zotefoams, will make the following statement:

Trading in the four months ended 30 April 2023 was strong, with the Group delivering continued year-on-year revenue growth and with margins benefiting from pricing, operational efficiency initiatives and a stronger US dollar. In addition, levels of input cost inflation were lower in the period and the Group has also benefitted from the phasing of planned SG&A spend increases.

Highlights, against the comparative prior year period, were:

Group sales increased by 15%

Polyolefin Foams sales increased by 14%:

- Volumes declined by 5%, primarily due to market-specific factors in continental Europe, which was more than offset by higher average selling prices as a result of previously implemented increases, favourable exchange rates and product mix

High-Performance Products (HPP) sales increased by 19%:

- Footwear sales grew strongly, with a 12% increase in volumes and a higher average selling price, primarily due to the stronger US dollar but also with a slightly more favourable product mix

- Sales volumes of ZOTEK® F technical foams for aviation and other markets declined by 13%. A relatively slow start to the year belies an improved demand environment

- T-FIT® insulation products sales were at a similar level

- In line with the normal seasonality of our business, our HPP business represents a smaller share of total revenue at this stage in the year

MuCell Extrusion's focus is on the technical and commercial development of ReZorce® mono-material packaging solutions. In the period, the business unit has:

- Transitioned its initial raw material formulations to its facility in Denmark in preparation for commercial trials in Europe for ReZorce cartons

- Made good progress on downstream processing of ReZorce sheet for cartons using off-the shelf commercial processing equipment

Cash generation and management has been strong in the period, with the leverage ratio being around 1.1x on a trailing 12-month basis, improved from 1.2x at 31 December 2022.

 

While the macroeconomic environment remains uncertain, the cost environment for the Group has improved in the early part of 2023.

Pricing for LDPE (the main material used in polyolefin foams) is relatively stable and at levels which are significantly lower than the all-time highs seen in 2022, albeit higher than long-term historic average pricing. Energy costs have also fallen from recent highs, but market prices remain volatile and forward prices are significantly higher than spot price as a result. Other cost inflation has generally been moderate with the exception of speciality polymers and wage inflation.

In the previous two years, Zotefoams has reacted to input-price movements by increasing selling prices and focusing on internal efficiencies and controllable costs, while proactively implementing actions to mitigate supply chain risks. In the period, there have been no major pricing actions and the current focus in Polyolefin Foams is to align the Group's product offering and pricing with the value its products deliver across markets globally.

Outlook

The Board anticipates further sales growth in the year to come primarily from the HPP portfolio, with good opportunities across all product groups. Prospects for volume growth in the Polyolefin Foams business unit are more reliant on general industrial market conditions, which we expect to remain challenging everywhere except for North America. At current exchange rates, the Board expects little impact from currency on full-year profit.

Internally, the Group is well-positioned to deliver further operational improvements and its spending plans are focused on key deliverables. This includes a significant spend on the ReZorce mono-material packaging development within the MuCell Extrusion business unit.

Performance in the early part of the year evidences continued demand for the Group's products together with its resilient operating platform. While being mindful of remaining macroeconomic volatility, the Board's full year expectations remain unchanged and it is confident about the long-term prospects of the business.

Chair Succession

As previously announced, Steve Good, who has been Chair of Zotefoams plc since 2016 and a non-executive director since 2014, will step down from the Board following the conclusion of the 2023 AGM. Steve will be replaced as Chair by Dr Lynn Drummond.

 

Commenting on the update David Stirling, Group CEO of Zotefoams, said: 

"I am pleased with the business performance in the first four months of the year and also the progress made on ReZorce carton development. The business has opportunities for growth in a number of HPP markets and better margins in Polyolefin Foams reflect pricing and cost management actions taken over the past year. With good cash generation and management, the business is well placed for further growth.

"It has been a pleasure to work with Steve Good as a fellow Director since 2014 and Chair since 2016, over which time the business has experienced strong growth and transformational change, which has included significant investment in global manufacturing capacity and in new product development. On behalf of the Board of Zotefoams plc and our management and staff, I thank Steve for his contribution to our success over the years and wish him all the best for the future." 

 

Note. The Board understands that current market expectations for the year ended 31 December 2023 are revenue of £135m and adjusted profit before tax of £12.6m.

 

 

- Ends -

 

Enquiries:

 

Zotefoams plc

+44 (0) 208 664 1600

David Stirling, Group CEO

Gary McGrath, Group CFO

IFC Advisory (Financial PR & IR)

+44 (0) 203 934 6630

Graham Herring

Tim Metcalfe

Zach Cohen

 

About Zotefoams plc

Zotefoams plc (LSE - ZTF) is a world leader in cellular materials technology delivering optimal material solutions for the benefit of society. Utilising a variety of unique manufacturing processes, including environmentally friendly nitrogen expansion for lightweight AZOTE®polyolefin and ZOTEK® high-performance foams, Zotefoams sells to diverse markets worldwide. Zotefoams uses its own cellular materials to manufacture T-FIT® advanced insulation for demanding industrial markets. Zotefoams also owns and licenses patented microcellular foam technology to reduce plastic use in extrusion applications and for ReZorce® mono-material recyclable barrier packaging.

Zotefoams is headquartered in Croydon, UK, with additional manufacturing sites in Kentucky, USA and Brzeg, Poland (foam manufacture), Oklahoma, USA (foam products manufacture and conversion), Massachusetts, USA and Stilling, Denmark (microcellular foam technology) and Jiangsu Province, China (T-FIT).

www.zotefoams.com

AZOTE®, ZOTEK®, ReZorce® and T-FIT® are registered trademarks of Zotefoams plc.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTPPURUAUPWGMW
Date   Source Headline
7th Apr 20104:30 pmRNSDirector/PDMR Shareholding
29th Mar 20108:50 amRNSHolding(s) in Company
24th Mar 201012:46 pmRNSHolding(s) in Company
23rd Mar 20102:40 pmRNSDirector/PDMR Shareholding
15th Mar 20104:52 pmRNSDirector/PDMR Shareholding
9th Mar 20107:00 amRNSFinal Results
3rd Mar 20102:36 pmRNSHolding(s) in Company
10th Dec 20092:30 pmRNSTrading Statement
23rd Oct 20097:00 amRNSInterim Management Statement
9th Oct 20093:08 pmRNSHolding(s) in Company
8th Sep 20092:13 pmRNSHolding(s) in Company
18th Aug 20091:36 pmRNSDirector/PDMR Shareholding
11th Aug 20095:45 pmRNSHolding(s) in Company
11th Aug 20095:15 pmRNSHolding(s) in Company
11th Aug 20094:19 pmRNSHolding(s) in Company
10th Aug 200912:45 pmRNSHolding(s) in Company
4th Aug 20097:00 amRNSHalf Yearly Report
20th Jul 20091:42 pmRNSHolding(s) in Company
3rd Jul 20097:00 amRNSTrading Statement
17th Jun 20095:33 pmRNSHolding(s) in Company
5th Jun 200912:23 pmRNSDirector/PDMR Shareholding
19th May 200910:30 amRNSAnnual Information Update
12th May 200910:30 amRNSVoting Rights and Capital
7th May 20097:00 amRNSAGM Statement
7th Apr 200910:51 amRNSNotice of AGM
26th Mar 20097:00 amRNSAdditional Listing
18th Mar 20091:50 pmRNSDirector/PDMR Shareholding
16th Mar 20095:19 pmRNSDirector/PDMR Shareholding
10th Mar 20097:00 amRNSFinal Results
22nd Jan 200911:36 amRNSHolding(s) in Company
5th Jan 20091:19 pmRNSVoting Rights and Capital
19th Dec 20087:00 amRNSTrading Statement
12th Dec 200811:04 amRNSDirector/PDMR Shareholding
11th Dec 20082:20 pmRNSHolding(s) in Company
3rd Nov 20087:00 amRNSInterim Management Statement
30th Oct 20082:25 pmRNSAdditional Listing
14th Aug 20087:00 amRNSDirector/PDMR Shareholding
5th Aug 20087:00 amRNSInterim Results
9th Jul 20089:11 amRNSAcquires Stake
1st Jul 20087:00 amRNSTrading Update
5th Jun 20089:37 amRNSVoting rights and capital
23rd May 20085:38 pmRNSAnnual Information Update
8th May 20087:01 amRNSAGM Statement
14th Apr 20087:00 amRNSBlocklisting Interim Review
8th Apr 20086:07 pmRNSAdditional Listing
8th Apr 20088:18 amRNSNotice of AGM
25th Mar 20082:46 pmRNSDirector/PDMR Shareholding
4th Mar 20087:01 amRNSFinal Results
3rd Mar 20087:00 amRNSCustomer Achievement
1st Feb 20081:46 pmRNSTotal Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.